Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT05848011).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:12 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

MacroGenics publicly tied the Phase 2 LORIKEET trial (NCT05848011) to a negative interim readout: it said the study’s experimental arm was not expected to achieve the primary rPFS goal versus control, and the company ended further prostate-cancer development.

Sources
Sponsorir.macrogenics.com11/12/25
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Company said that after reviewing interim LORIKEET data, it would not pursue further prostate-cancer development; with an Oct. 17, 2025 cutoff, the experimental arm was not expected to reach the primary rPFS goal vs control.

View source
ClinicalTrialsclinicaltrials.gov12/1/25
Study Details | NCT05848011 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

ClinicalTrials.gov identifies NCT05848011 as the Phase 2 randomized study of lorigerlimab plus docetaxel/prednisone versus docetaxel/prednisone in metastatic castration-resistant prostate cancer.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

MacroGenics publicly tied the Phase 2 LORIKEET trial (NCT05848011) to a negative interim readout: it said the study’s experimental arm was not expected to achieve the primary rPFS goal versus control, and the company ended further prostate-cancer development.

Found Apr 1, 2026, 7:12 PMOutcome date Nov 12, 2025, 12:00 AMReviewed Apr 1, 2026, 7:16 PM
Sponsorir.macrogenics.comNov 12, 2025, 12:00 AM
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
Company said that after reviewing interim LORIKEET data, it would not pursue further prostate-cancer development; with an Oct. 17, 2025 cutoff, the experimental arm was not expected to reach the primary rPFS goal vs control.
ClinicalTrialsclinicaltrials.govDec 1, 2025, 12:00 AM
Study Details | NCT05848011 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov identifies NCT05848011 as the Phase 2 randomized study of lorigerlimab plus docetaxel/prednisone versus docetaxel/prednisone in metastatic castration-resistant prostate cancer.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:16 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)94% confidenceReviewed Apr 1, 2026, 7:16 PM

MacroGenics publicly tied the Phase 2 LORIKEET trial (NCT05848011) to a negative interim readout: it said the study’s experimental arm was not expected to achieve the primary rPFS goal versus control, and the company ended further prostate-cancer development.